Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205682
Max Phase: Preclinical
Molecular Formula: C39H50N6O7
Molecular Weight: 714.86
Associated Items:
ID: ALA5205682
Max Phase: Preclinical
Molecular Formula: C39H50N6O7
Molecular Weight: 714.86
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CCN1CCC(Oc2ccccc2Cc2ccccc2)CC1)C(=O)N[C@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C39H50N6O7/c1-26(37(49)41-27(2)38(50)44-32(36(40)48)24-29-13-7-4-8-14-29)42-39(51)33(25-46)43-35(47)19-22-45-20-17-31(18-21-45)52-34-16-10-9-15-30(34)23-28-11-5-3-6-12-28/h3-16,26-27,31-33,46H,17-25H2,1-2H3,(H2,40,48)(H,41,49)(H,42,51)(H,43,47)(H,44,50)/t26-,27-,32+,33-/m0/s1
Standard InChI Key: GKWUHNUTOQPEJK-LWYBVUOESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 714.86 | Molecular Weight (Monoisotopic): 714.3741 | AlogP: 1.21 | #Rotatable Bonds: 18 |
Polar Surface Area: 192.19 | Molecular Species: BASE | HBA: 8 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.67 | CX Basic pKa: 8.73 | CX LogP: 1.31 | CX LogD: -0.04 |
Aromatic Rings: 3 | Heavy Atoms: 52 | QED Weighted: 0.11 | Np Likeness Score: -0.31 |
1. Kok ZY, Stoddart LA, Mistry SJ, Mocking TAM, Vischer HF, Leurs R, Hill SJ, Mistry SN, Kellam B.. (2022) Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor., 65 (12.0): [PMID:35734860] [10.1021/acs.jmedchem.2c00125] |
Source(1):